These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24930060)

  • 1. Diabetes and cancer: 5 years into the recent controversy.
    Badrick E; Renehan AG
    Eur J Cancer; 2014 Aug; 50(12):2119-25. PubMed ID: 24930060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
    McFarland MS; Cripps R
    Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes therapy and cancer risk: causal effects and other plausible explanations.
    Hernández-Díaz S; Adami HO
    Diabetologia; 2010 May; 53(5):802-8. PubMed ID: 20177658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk in diabetic patients treated with insulin glargine?
    Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and pancreatic cancer.
    Chaudhry ZW; Hall E; Kalyani RR; Cosgrove DP; Yeh HC
    Curr Probl Cancer; 2013; 37(5):287-92. PubMed ID: 24331184
    [No Abstract]   [Full Text] [Related]  

  • 9. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
    Bowker SL; Lin M; Eurich DT; Johnson JA
    Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
    Kowall B; Rathmann W; Kostev K
    Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus and the risk of cancer.
    Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
    Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
    Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
    Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer risks from diabetes therapies: evaluating the evidence.
    Li C; Kong D
    Pharmacol Ther; 2014 Oct; 144(1):71-81. PubMed ID: 24844968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
    Butler PC
    Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
    [No Abstract]   [Full Text] [Related]  

  • 16. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
    Colhoun HM;
    Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
    Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
    Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
    Hosio M; Urpilainen E; Marttila M; Hautakoski A; Arffman M; Sund R; Puistola U; Läärä E; Jukkola A; Karihtala P
    Breast Cancer Res Treat; 2019 Jun; 175(3):741-748. PubMed ID: 30895533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insulins and the risk of cancer.
    Danne T; Bolinder J
    Int J Clin Pract Suppl; 2010 Feb; (166):26-8. PubMed ID: 20377661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.